📝 Find notes here: https://www.nonstopneuron.com/post/cl...
🌐 Explore our entire animation video library: https://www.nonstopneuron.com/
● Follow me at:
• Instagram: / nonstopneuron
• Facebook: / nonstopneuron
Classification of Adrenergic Drugs
Classification of adrenergic drugs includes endogenous catecholamines, drugs that act directly on the receptors, indirectly acting drugs, and mixed-acting sympathomimetics. Endogenous catecholamines are epinephrine, norepinephrine, and dopamine. Selective α1 agonists are phenylephrine, methoxamine, and midodrine. Selective α2 agonists are clonidine, methyldopa, guanfacine, guanabenz, moxonidine, rilmenidine, dexmedetomidine, tizanidine, naphazoline, xylometazoline, oxymetazoline, apraclonidine, and brimonidine. Isoproterenol is a nonselective β agonist. Dobutamine is β1 subtype-selective agonist. Selective β2 agonists are salbutamol, terbutaline, salmeterol, formoterol, ritodrine and isoxuprine. Amphetamine-like drugs, which increase transmitter release are amphetamine, methamphetamine, methylphenidate, modafinil, and tyramine. Catecholamine reuptake inhibitors are imipramine, amitriptyline, sibutramine, duloxetine, milnacipran, atomoxetine, and cocaine. Mixed actin sympathomimetic drugs are ephedrine, mephentermine, and pseudoephedrine.
Dr Vipul Navadiya
Chapters:
00:00 Introduction
01:21 Endogenous Catecholamines
05:40 Direct Acting Sympathomimetics
12:13 Indirect Acting Sympathomimetics
16:51 Mixed Acting Sympathomimetics
17:55 Summary
DISCLAIMER: This video is for education purposes only. Although every effort is made to ensure the accuracy of the material, viewers should refer to the appropriate regulatory body/authorized websites, guidelines, and other suitable sources of information as deemed relevant and applicable. In view of the possibility of human error or changes in medical science, any person or organization involved in the preparation of this work accepts no responsibility for any errors or omissions, or results obtained from the use of information in this video.
Информация по комментариям в разработке